secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0000950170-24-039736
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro licenses STRO-003 ADC to Ipsen for up to $900M; $50M upfront plus equity
------------------------------------------------------------------------------

- Exclusive global license to Sutro's STRO-003 (ROR1-targeting ADC) to Ipsen; total potential $900M.
- $50M upfront license fee plus $25M equity investment (4.8M shares at 17% premium to 20-day VWAP).
- Up to $447M in development/regulatory milestones and up to $360M in sales milestones.
- Tiered royalties from low double-digit to mid-teen percentages on net sales.
- Ipsen responsible for IND submission and all subsequent clinical/commercial activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024039736/0000950170-24-039736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024039736/stro-20240329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer